Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals

Erasca Inc ERAS said that due to a lack of clinical activity, it would not continue exploring ERAS-007 combined with palbociclib in patients with RAS-mutated gastrointestinal malignancies or ERAS-007 combined with osimertinib in patients with post-osimertinib EGFR-mutated non-small cell lung cancer.
The company will deprioritize certain discovery programs: ERAS-9 (SOS1), ERAS-11 (MYC), and ERAS-2/3 (RAS switch-II groove targeting), but is pursuing other promising research approaches to target RAS mutations beyond G12C.
Erasca also announced preliminary Phase 1b data for ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC).
50% (3/6) response rate, including two confirmed partial responses (cPR) and one unconfirmed partial response (uPR), and a 67% (4/6) disease control rate (DCR) was observed at the highest dose of ERAS-007 tested (100 mg BID-QW).
Across all dose levels in EC-naïve response evaluable patients, 38% (3/8) response rate, including two cPRs and one uPR, and 63% (5/8) DCR.
ERAS-007 + EC was generally well tolerated, with primarily low-grade treatment-related adverse events (TRAEs) at all combination doses. No Grade 4 or 5 TRAEs were observed.
One dose-limiting toxicity was reported for ERAS-007 100 mg BID-QW + EC (Grade 3 macular edema)
Price Action: ERAS shares closed at $3.30 on Monday.